S'abonner

Respiratory allergy caused by house dust mites: What do we really know? - 03/07/15

Doi : 10.1016/j.jaci.2014.10.012 
Moisés A. Calderón, MD, PhD a, , Allan Linneberg, MD, PhD b, Jörg Kleine-Tebbe, MD c, Frédéric De Blay, MD, PhD d, Dolores Hernandez Fernandez de Rojas, MD, PhD e, Johann Christian Virchow, MD, FRCP, FCCP f, Pascal Demoly, MD, PhD g
a Section of Allergy and Clinical Immunology, Imperial College London–NHLI, Royal Brompton Hospital, London, United Kingdom 
b Research Centre for Prevention and Health, Capital Region of Denmark, the Department of Clinical Experimental Research, Glostrup University Hospital, and the Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark 
c Allergy and Asthma Center Westend Outpatient Clinic Hanf, Ackermann & Kleine-Tebbe, Berlin, Germany 
d Chest Diseases Department, Hôpitaux Universitaires de Strasbourg, Fédération de médecine translationnelle, Université de Strasbourg, Strasbourg, France 
e Department of Allergy, IIS Hospital La Fe, Valencia, Spain 
f Department of Pneumology and Intensive Care Medicine, Zentrum für Innere Medizin, Klinik I, Universitätsklinikum Rostock, Rostock, Germany 
g Department of Pulmonology, Division of Allergy, University Hospital of Montpellier, and Sorbonne Universités, Paris, France 

Corresponding author: Moisés A. Calderón, MD, PhD, Section of Allergy and Clinical Immunology, Imperial College London–NHLI, Royal Brompton Hospital, London SW3 6LY, United Kingdom.

Abstract

The house dust mite (HDM) is a major perennial allergen source and a significant cause of allergic rhinitis and allergic asthma. However, awareness of the condition remains generally low. This review assesses the links between exposure to HDM, development of the allergic response, and pathologic consequences in patients with respiratory allergic diseases. We investigate the epidemiology of HDM allergy to explore the interaction between mites and human subjects at the population, individual, and molecular levels. Core and recent publications were identified by using “house dust mite” as a key search term to evaluate the current knowledge of HDM epidemiology and pathophysiology. Prevalence data for HDM allergen sensitization vary from 65 to 130 million persons in the general population worldwide to as many as 50% among asthmatic patients. Heterogeneity of populations, terminology, and end points in the literature confound estimates, indicating the need for greater standardization in epidemiologic research. Exposure to allergens depends on multiple ecological strata, including climate and mite microhabitats within the domestic environment, with the latter providing opportunity for intervention measures to reduce allergen load. Inhaled mite aeroallergens are unusually virulent: they are able to activate both the adaptive and innate immune responses, potentially offering new avenues for intervention. The role of HDM allergens is crucial in the development of allergic rhinitis and asthma, but the translation of silent sensitization into symptomatic disease is still incompletely understood. Improved understanding of HDMs, their allergens, and their microhabitats will enable development of more effective outcomes for patients with HDM allergy.

Le texte complet de cet article est disponible en PDF.

Key words : Allergen, house dust mite, allergy, allergic asthma, allergic rhinitis, respiratory allergic disease, inflammation

Abbreviation used : HDM


Plan


 An educational grant for the development of this article was provided by ALK-Abelló.
 Disclosure of potential conflict of interest: This study was funded by ALK-Abelló, Hørsholm, Denmark. M. A. Calderón has received compensation for board membership from ALK-Abelló and Stallergenes; has received consultancy fees from ALK-Abelló, Merck, Stallergenes, HAL Allergy, and Allergopharma, as well as payment for delivering lectures from ALK-Abelló, Merck, Stallergenes, and Allergopharma; and has received compensation for travel and other meeting-related expenses from ALK-Abelló, Merck, Stallergenes, and Allergopharma. A. Linneberg has received payment for delivering lectures from ALK-Abelló. J. Kleine-Tebbe has received or has grants pending from Circassia and has received compensation for board membership from ALK-Abelló, Novartis, and LETI, as well as consultancy fees from Merck, and has received payment for delivering lectures from Allergopharma, ALK-Abelló, Bencard, HAL Allergy, LETI Lofarma, Novartis, and Stallergenes. F. De Blay has received funding from Stallergenes and Chiesi; consultancy fees from Stallergenes, ALK-Abelló, Mundipharma, and Novartis; fees for participation in review activities from ALK-Abelló and Stallergenes; and compensation for board membership from Stallergenes, ALK-Abelló, Mundipharma, Novartis, and Same. J. C. Virchow has received consultancy fees from ALK-Abelló, as well as payment for delivering lectures. P. Demoly has received consultancy fees from ALK-Abelló, Circassia, Stallergenes, Allergopharma, Chiesi, Pierre Fabre Médicaments, and Ménarini and has received payment for delivering lectures from Ménarini, MSD, AstraZeneca, and GlaxoSmithKline. D. Hernandez Fernandez de Rojas declares no other relevant conflict of interest.


© 2014  The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 136 - N° 1

P. 38-48 - juillet 2015 Retour au numéro
Article précédent Article précédent
  • 100 Years later: Celebrating the contributions of x-ray crystallography to allergy and clinical immunology
  • Anna Pomés, Maksymilian Chruszcz, Alla Gustchina, Wladek Minor, Geoffrey A. Mueller, Lars C. Pedersen, Alexander Wlodawer, Martin D. Chapman
| Article suivant Article suivant
  • The Editors' Choice
  • Donald Y.M. Leung, Stanley J. Szefler, Associate Editors of the JACI

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.